Outcomes with trastuzumab deruxtecan by biomarker status, line oftreatment and prior receipt of sacituzumab govitecan in a large real-worlddatabase of patients with metastatic breast cancer Por Kati Outcomes with trastuzumab deruxtecan by biomarker status, line oftreatment and prior receipt of sacituzumab govitecan in a large real-worlddatabase of patients with metastatic breast cancer Read More »
Efficacy of Presurgical Short-Term Endocrine Therapy During theWaiting Period for Surgery in Postmenopausal HormoneReceptor-Positive Breast Cancer Por Kati Efficacy of Presurgical Short-Term Endocrine Therapy During theWaiting Period for Surgery in Postmenopausal HormoneReceptor-Positive Breast Cancer Read More »
Omitting Regional Nodal Irradiation afterResponse to Neoadjuvant Chemotherapy Por Kati Omitting Regional Nodal Irradiation afterResponse to Neoadjuvant Chemotherapy Read More »
Implications of omitting sentinel lymph node biopsy onadjuvant decision making for patients with small breastcancers Por Kati Implications of omitting sentinel lymph node biopsy onadjuvant decision making for patients with small breastcancers Read More »
The role of sentinel lymph biopsy in patients with microinvasive breastcancer: A multicentric study Por Kati The role of sentinel lymph biopsy in patients with microinvasive breastcancer: A multicentric study Read More »
Beta blocker use and breast cancer survival by subtypes: Apopulation-based cohort study Por Kati Beta blocker use and breast cancer survival by subtypes: Apopulation-based cohort study Read More »
Great Debate: Does Breast‑Conserving Surgerywith Radiotherapy Ofer Better Survival than Mastectomyin Early‑Stage Breast Cancer? Por Kati Great Debate: Does Breast‑Conserving Surgerywith Radiotherapy Ofer Better Survival than Mastectomyin Early‑Stage Breast Cancer? Read More »
Body composition metrics as adeterminant of trastuzumab deruxtecanrelated toxicity and response Por Kati Body composition metrics as adeterminant of trastuzumab deruxtecanrelated toxicity and response Read More »
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclibplus endocrine therapy in advanced HR+/HER2- BC patients: results from themulticenter PALMARES-2 study Por Kati Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclibplus endocrine therapy in advanced HR+/HER2- BC patients: results from themulticenter PALMARES-2 study Read More »
Downstream Efects of Omission of Axillary Surgery in OlderAdults with Early‑Stage H Por Kati Downstream Efects of Omission of Axillary Surgery in OlderAdults with Early‑Stage H Read More »
Second-Line Endocrine Therapy With or Without PalbociclibRechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–NegativeAdvanced Breast Cancer: PALMIRA Trial Por Kati Second-Line Endocrine Therapy With or Without PalbociclibRechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–NegativeAdvanced Breast Cancer: PALMIRA Trial Read More »
Postmastectomy Radiation Therapy forIntermediate-Risk Breast Cancer Patients With0-3 Positive Axillary Lymph Nodes: Emulatingthe SUPREMO Trial Using Real-World Data Por Kati Postmastectomy Radiation Therapy forIntermediate-Risk Breast Cancer Patients With0-3 Positive Axillary Lymph Nodes: Emulatingthe SUPREMO Trial Using Real-World Data Read More »
